About zealand pharma a/s - ZLDPF
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
ZLDPF At a Glance
Zealand Pharma A/S
Sydmarken 11
Soborg, Zealand 2860
| Phone | 45-88-77-36-00 | Revenue | 9.09M | |
| Industry | Biotechnology | Net Income | -156,454,453.61 | |
| Sector | Health Technology | Employees | 335 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ZLDPF Valuation
| P/E Current | 4.412 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 725.992 |
| Price to Book Ratio | 5.867 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -30.575 |
| Enterprise Value to Sales | 606.338 |
| Total Debt to Enterprise Value | 0.01 |
ZLDPF Efficiency
| Revenue/Employee | 27,139.142 |
| Income Per Employee | -467,028.22 |
| Receivables Turnover | 0.225 |
| Total Asset Turnover | 0.009 |
ZLDPF Liquidity
| Current Ratio | 21.136 |
| Quick Ratio | 21.109 |
| Cash Ratio | 20.388 |
ZLDPF Profitability
| Gross Margin | 46.211 |
| Operating Margin | -2,024.327 |
| Pretax Margin | -1,728.231 |
| Net Margin | -1,720.866 |
| Return on Assets | -15.585 |
| Return on Equity | -21.843 |
| Return on Total Capital | -12.507 |
| Return on Invested Capital | -20.862 |
ZLDPF Capital Structure
| Total Debt to Total Equity | 4.546 |
| Total Debt to Total Capital | 4.349 |
| Total Debt to Total Assets | 3.547 |
| Long-Term Debt to Equity | 4.36 |
| Long-Term Debt to Total Capital | 4.171 |